232 related articles for article (PubMed ID: 24080690)
1. India's patent ecosystem - encouraging strong patents or discouraging innovation?
Harrison C
Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690
[No Abstract] [Full Text] [Related]
2. Novartis challenges India's drug patent laws in Supreme Court.
Billingsley M
BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
[No Abstract] [Full Text] [Related]
3. Changes to India's patent law may deny cheap drugs to millions.
Mudur G
BMJ; 2005 Mar; 330(7493):692. PubMed ID: 15790640
[No Abstract] [Full Text] [Related]
4. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
Moszynski P
BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
[No Abstract] [Full Text] [Related]
5. India's new patent laws may still hurt generic drug supplies.
Chatterjee P
Lancet; 2005 Apr 16-22; 365(9468):1378. PubMed ID: 15841559
[No Abstract] [Full Text] [Related]
6. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
7. India's rejection of Novartis's patent is but a small step in the right direction.
Bhaumik S
BMJ; 2013 Apr; 346():f2412. PubMed ID: 23596223
[No Abstract] [Full Text] [Related]
8. India's patent laws under pressure.
Roderick P; Pollock AM
Lancet; 2012 Sep; 380(9846):e2-4. PubMed ID: 22988579
[No Abstract] [Full Text] [Related]
9. Impact of India's new patents law 2005: a physician's perspective.
Lele RD
J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
[No Abstract] [Full Text] [Related]
10. India's patent laws and the multinational pharmaceutical industry.
Srinivasan S; Bharadwaj K
Natl Med J India; 2013; 26(3):128-32. PubMed ID: 24476157
[No Abstract] [Full Text] [Related]
11. India's IP snub.
Jayaraman KS
Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
[No Abstract] [Full Text] [Related]
12. Recent developments in health law. India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent.
Chilton A
J Law Med Ethics; 2011; 39(2):296-300. PubMed ID: 21710799
[No Abstract] [Full Text] [Related]
13. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
14. India's patent case victory rattles Big Pharma.
Chatterjee P
Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911
[No Abstract] [Full Text] [Related]
15. Big Pharma vs India’s Patent Office.
Pharm Pat Anal; 2012 Nov; 1(5):529. PubMed ID: 24236921
[No Abstract] [Full Text] [Related]
16. India’s IP appellate board upholds Pfizer’s detrol® patent.
Pharm Pat Anal; 2014 May; 3(3):223. PubMed ID: 24998285
[No Abstract] [Full Text] [Related]
17. Patent battle lines drawn as sofosbuvir gains approval.
Harrison C
Nat Rev Drug Discov; 2014 Jan; 13(1):12. PubMed ID: 24378791
[No Abstract] [Full Text] [Related]
18. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
Manthei JR; Hathaway CR; Grant MA; Chung DD
Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032
[No Abstract] [Full Text] [Related]
19. Will the refusal of patent protection for Glivec® discourage future pharmaceutical innovation in India?
Albutt J
Pharm Pat Anal; 2013 Jul; 2(4):439-41. PubMed ID: 24237119
[No Abstract] [Full Text] [Related]
20. Navigating the Hatch-Waxman Act's safe harbor.
Jones PB
Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
[No Abstract] [Full Text] [Related]
[Next] [New Search]
